Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2016; 22(29): 6582-6594
Published online Aug 7, 2016. doi: 10.3748/wjg.v22.i29.6582
Progress in systemic therapy of advanced hepatocellular carcinoma
Xin-Lei Gong, Shu-Kui Qin
Xin-Lei Gong, Shu-Kui Qin, Chinese People’s Liberation Army Cancer Center, Bayi Hospital, Nanjing 210002, Jiangsu Province, China
Author contributions: Both authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: The authors declare no potential conflicts of interest or financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Shu-Kui Qin, MD, Chinese People’s Liberation Army Cancer Center, Bayi Hospital, No. 34, 34 Biao, Yanggongjing Street, Nanjing 210002, Jiangsu Province, China. qinsk@csco.org.cn
Telephone: +86-25-84453932 Fax: +86-25-84453906
Received: March 30, 2016
Peer-review started: April 5, 2016
First decision: May 12, 2016
Revised: May 27, 2016
Accepted: June 29, 2016
Article in press: June 29, 2016
Published online: August 7, 2016
Processing time: 121 Days and 10.7 Hours
Core Tip

Core tip: This review describes the progress in systemic therapy of advanced hepatocellular carcinoma (HCC) in recent years from several aspects. First, we describe the progress in molecular targeted therapy of HCC. Second, we highlight systemic chemotherapy especially oxaliplatin-based regimens. Third, we introduce some new information of immunotherapy and arginine deprivation therapy. At the end of the article, we have a brief summary and discuss the future direction of development.